organization · Reporting owner
NEUROCRINE BIOSCIENCES INC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | 10% owner | February 23, 2023 | February 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date February 23, 2023 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,575,316 |
Reported balance
After 2023-02-23 transaction · row 1
1 source rowRow 1 · 2023-02-23 · Purchase · Acquired 4,395,588 · Balance 8,575,316 F1: The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2023 Filed Feb 24, 2023 11:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | PurchaseCommon Stock | 4,395,588 | $8.88 | $39,032,821.44 |
DisclosureSEC source: 0000899243-23-006093 · doc4.xml · nonDerivative · entry 1 NEUROCRINE BIOSCIENCES INC · CIK 0000914475 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,575,316 F1 · price: The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 20:34 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | PurchaseCommon Stock | 4,179,728 | $11.96 | $49,999,996.20 |
DisclosureSEC source: 0001209191-19-019459 · doc4.xml · nonDerivative · entry 1 NEUROCRINE BIOSCIENCES INC · CIK 0000914475 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179,728 F1 · price: The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 28, 2019 between the reporting person and the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.